Cargando…
The Diagnostic Role of FGF 21 in Endometrial Cancer and Other Pathologies of the Uterine Corpus
Endometrial cancer is becoming an increasing problem. Taking into account its pathomechanisms, we aimed to investigate whether FGF 21, an important metabolism regulator, could be used as a biomarker for endometrial cancer. The study included 233 patients who were classified into five subgroups depen...
Autores principales: | Jagodzińska, Anna, Chudecka-Głaz, Anita, Michalczyk, Kaja, Pius-Sadowska, Ewa, Wieder-Huszla, Sylwia, Jurczak, Anna, Machaliński, Bogusław |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914808/ https://www.ncbi.nlm.nih.gov/pubmed/36766504 http://dx.doi.org/10.3390/diagnostics13030399 |
Ejemplares similares
-
The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients
por: Cymbaluk-Płoska, Aneta, et al.
Publicado: (2020) -
Evaluation of biologically active substances promoting the development of or protecting against endometrial cancer
por: Cymbaluk-Płoska, Aneta, et al.
Publicado: (2018) -
Evaluation of He4 Use in the Diagnosis of Ovarian Cancer: First and Second Recurrence, and an Analysis of HE4 Concentration during Second- and Third-Line Chemotherapy
por: Chudecka-Głaz, Anita, et al.
Publicado: (2023) -
Circulating Serum Level of Visfatin in Patients with Endometrial Cancer
por: Cymbaluk-Płoska, Aneta, et al.
Publicado: (2018) -
Clinical importance of serum HE4 and MMP2 levels in endometrial cancer patients
por: Cymbaluk-Płoska, Aneta, et al.
Publicado: (2017)